Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control

NCT00283179 is registered in ClinicalTrials.gov with Taiwan Otsuka Pharm. Co., Ltd as lead sponsor.

NCT NCT00283179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00283179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control
Lead sponsor
Taiwan Otsuka Pharm. Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2004
Completion date
December 31, 2004
Enrollment
83 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia